Core Scientific [CORZ] vs Oracle [ORCL] Detailed Stock Comparison
Core Scientific
NASDAQ
Loading...
Oracle
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Core Scientific wins in 8 metrics, Oracle wins in 9 metrics, with 0 ties. Oracle appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Core Scientific | Oracle | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.09 | 54.06 | Core Scientific |
| Price-to-Book Ratio | -4.05 | 32.20 | Core Scientific |
| Debt-to-Equity Ratio | -1.09 | 519.59 | Core Scientific |
| PEG Ratio | 0.03 | 32.77 | Core Scientific |
| EV/EBITDA | -86.45 | 32.24 | Core Scientific |
| Profit Margin (TTM) | 23.71% | 21.68% | Core Scientific |
| Operating Margin (TTM) | -28.13% | 32.48% | Oracle |
| EBITDA Margin (TTM) | N/A | 32.48% | N/A |
| Return on Equity | 160.33% | 82.38% | Core Scientific |
| Return on Assets (TTM) | -6.74% | 7.26% | Oracle |
| Free Cash Flow (TTM) | $-52.30M | $-394.00M | Core Scientific |
| Dividend Yield | N/A | 0.81% | N/A |
| 1-Year Return | 25.93% | 69.82% | Oracle |
| Price-to-Sales Ratio (TTM) | 11.88 | 11.48 | Oracle |
| Enterprise Value | $4.72B | $757.28B | Oracle |
| EV/Revenue Ratio | 13.55 | 13.19 | Oracle |
| Gross Profit Margin (TTM) | 6.39% | 70.19% | Oracle |
| Revenue per Share (TTM) | $1 | $21 | Oracle |
| Earnings per Share (Diluted) | $-1.73 | $4.34 | Oracle |
| Beta (Stock Volatility) | N/A | 1.43 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Core Scientific vs Oracle Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Core Scientific | -1.74% | -4.10% | 0.52% | 25.12% | 37.42% | -6.42% |
| Oracle | 1.38% | -4.80% | -0.73% | 50.26% | 39.07% | 42.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Core Scientific | 25.93% | 291.62% | 291.62% | 291.62% | 291.62% | 291.62% |
| Oracle | 69.82% | 216.64% | 308.38% | 530.99% | 950.07% | 1,732.33% |
Performance & Financial Health Analysis: Core Scientific vs Oracle
| Metric | CORZ | ORCL |
|---|---|---|
| Market Information | ||
| Market Cap | $4.14B | $659.01B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 22,691,300 | 10,879,370 |
| 90 Day Avg. Volume | 17,220,423 | 10,546,587 |
| Last Close | $13.55 | $236.37 |
| 52 Week Range | $6.20 - $18.63 | $118.86 - $260.87 |
| % from 52W High | -27.26% | -9.39% |
| All-Time High | $18.63 (Nov 25, 2024) | $260.87 (Jul 31, 2025) |
| % from All-Time High | -27.27% | -9.39% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.44% | 0.11% |
| Quarterly Earnings Growth | -0.44% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.24% | 0.22% |
| Operating Margin (TTM) | -0.28% | 0.32% |
| Return on Equity (TTM) | 1.60% | 0.82% |
| Debt to Equity (MRQ) | -1.09 | 519.59 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-3.51 | $7.29 |
| Cash per Share (MRQ) | $1.90 | $3.99 |
| Operating Cash Flow (TTM) | $12.92M | $20.82B |
| Levered Free Cash Flow (TTM) | $-125,378,624 | $678.00M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.81% |
| Last 12-Month Dividend | N/A | $1.70 |
Valuation & Enterprise Metrics Analysis: Core Scientific vs Oracle
| Metric | CORZ | ORCL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.09 | 54.06 |
| Forward P/E | 43.71 | 32.77 |
| PEG Ratio | 0.03 | 32.77 |
| Price to Sales (TTM) | 11.88 | 11.48 |
| Price to Book (MRQ) | -4.05 | 32.20 |
| Market Capitalization | ||
| Market Capitalization | $4.14B | $659.01B |
| Enterprise Value | $4.72B | $757.28B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 13.55 | 13.19 |
| Enterprise to EBITDA | -86.45 | 32.24 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.43 |
| Book Value per Share (MRQ) | $-3.51 | $7.29 |
Financial Statements Comparison: Core Scientific vs Oracle
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CORZ | ORCL |
|---|---|---|
| Revenue/Sales | $79.53M | $15.90B |
| Cost of Goods Sold | $71.31M | $4.74B |
| Gross Profit | $8.21M | $11.16B |
| Research & Development | N/A | $2.65B |
| Operating Income (EBIT) | $-42.59M | $5.19B |
| EBITDA | $-641.64M | $7.00B |
| Pre-Tax Income | $580.90M | $4.15B |
| Income Tax | $205,000 | $725.00M |
| Net Income (Profit) | $580.69M | $3.43B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CORZ | ORCL |
|---|---|---|
| Cash & Equivalents | $697.94M | $10.79B |
| Total Current Assets | $833.18M | $24.58B |
| Total Current Liabilities | $195.51M | $32.64B |
| Long-Term Debt | $1.17B | $96.83B |
| Total Shareholders Equity | $-181.51M | $20.97B |
| Retained Earnings | $-3.15B | $-15.48B |
| Property, Plant & Equipment | $610.44M | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CORZ | ORCL |
|---|---|---|
| Operating Cash Flow | $590.74M | $5.93B |
| Capital Expenditures | $-88.42M | N/A |
| Free Cash Flow | $-129.06M | $-2.92B |
| Debt Repayment | $-4.46M | $-6.07B |
| Common Stock Repurchase | N/A | $-150.00M |
Short Interest & Institutional Ownership Analysis
| Metric | CORZ | ORCL |
|---|---|---|
| Shares Short | 57.61M | 20.69M |
| Short Ratio | 2.57 | 1.58 |
| Short % of Float | 0.19% | 0.01% |
| Average Daily Volume (10 Day) | 22,691,300 | 10,879,370 |
| Average Daily Volume (90 Day) | 17,220,423 | 10,546,587 |
| Shares Outstanding | 292.61M | 2.81B |
| Float Shares | 295.64M | 1.64B |
| % Held by Insiders | 0.07% | 0.42% |
| % Held by Institutions | 0.94% | 0.45% |
Dividend Analysis & Yield Comparison: Core Scientific vs Oracle
| Metric | CORZ | ORCL |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.70 |
| Last 12-Month Dividend Yield | N/A | 0.81% |
| 3-Year Avg Annual Dividend | N/A | $1.55 |
| 3-Year Avg Dividend Yield | N/A | 0.36% |
| 3-Year Total Dividends | N/A | $4.66 |
| Ex-Dividend Date | N/A | Apr 10, 2025 |